These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. ERG and SALL4 expressions in SMARCB1/INI1-deficient tumors: a useful tool for distinguishing epithelioid sarcoma from malignant rhabdoid tumor. Kohashi K; Yamada Y; Hotokebuchi Y; Yamamoto H; Taguchi T; Iwamoto Y; Oda Y Hum Pathol; 2015 Feb; 46(2):225-30. PubMed ID: 25479928 [TBL] [Abstract][Full Text] [Related]
10. SMARCB1-deficient Tumors of Childhood: A Practical Guide. Pawel BR Pediatr Dev Pathol; 2018; 21(1):6-28. PubMed ID: 29280680 [TBL] [Abstract][Full Text] [Related]
11. The genetic landscape of SMARCB1 alterations in SMARCB1-deficient spectrum of mesenchymal neoplasms. Dermawan JK; Singer S; Tap WD; Nacev BA; Chi P; Wexler LH; Ortiz MV; Gounder M; Antonescu CR Mod Pathol; 2022 Dec; 35(12):1900-1909. PubMed ID: 36088476 [TBL] [Abstract][Full Text] [Related]
12. SMARCB1 expression in epithelioid sarcoma is regulated by miR-206, miR-381, and miR-671-5p on Both mRNA and protein levels. Papp G; Krausz T; Stricker TP; Szendrői M; Sápi Z Genes Chromosomes Cancer; 2014 Feb; 53(2):168-76. PubMed ID: 24327545 [TBL] [Abstract][Full Text] [Related]
13. SMARCB1/INI1 tumor suppressor gene is frequently inactivated in epithelioid sarcomas. Modena P; Lualdi E; Facchinetti F; Galli L; Teixeira MR; Pilotti S; Sozzi G Cancer Res; 2005 May; 65(10):4012-9. PubMed ID: 15899790 [TBL] [Abstract][Full Text] [Related]
14. Re: Infrequent SMARCB1/INI1 gene alteration in epithelioid sarcoma: a useful tool in distinguishing epithelioid sarcoma from malignant rhabdoid tumor: Direct evidence of mutational inactivation of SMARCB1/INI1 in epithelioid sarcoma. Flucke U; Slootweg PJ; Mentzel T; Pauwels P; Hulsebos TJ Hum Pathol; 2009 Sep; 40(9):1361-2; author reply 1362-4. PubMed ID: 19683621 [No Abstract] [Full Text] [Related]
15. Consistent SMARCB1 homozygous deletions in epithelioid sarcoma and in a subset of myoepithelial carcinomas can be reliably detected by FISH in archival material. Le Loarer F; Zhang L; Fletcher CD; Ribeiro A; Singer S; Italiano A; Neuville A; Houlier A; Chibon F; Coindre JM; Antonescu CR Genes Chromosomes Cancer; 2014 Jun; 53(6):475-86. PubMed ID: 24585572 [TBL] [Abstract][Full Text] [Related]
16. Loss of IGFBP7 expression and persistent AKT activation contribute to SMARCB1/Snf5-mediated tumorigenesis. Darr J; Klochendler A; Isaac S; Eden A Oncogene; 2014 Jun; 33(23):3024-32. PubMed ID: 23851500 [TBL] [Abstract][Full Text] [Related]
17. SMARCB1-deficient Vulvar Neoplasms: A Clinicopathologic, Immunohistochemical, and Molecular Genetic Study of 14 Cases. Folpe AL; Schoolmeester JK; McCluggage WG; Sullivan LM; Castagna K; Ahrens WA; Oliva E; Biegel JA; Nielsen GP Am J Surg Pathol; 2015 Jun; 39(6):836-49. PubMed ID: 25651469 [TBL] [Abstract][Full Text] [Related]
18. Oncogenic roles of SMARCB1/INI1 and its deficient tumors. Kohashi K; Oda Y Cancer Sci; 2017 Apr; 108(4):547-552. PubMed ID: 28109176 [TBL] [Abstract][Full Text] [Related]
19. Epithelioid sarcoma is associated with a high percentage of SMARCB1 deletions. Sullivan LM; Folpe AL; Pawel BR; Judkins AR; Biegel JA Mod Pathol; 2013 Mar; 26(3):385-92. PubMed ID: 23060122 [TBL] [Abstract][Full Text] [Related]
20. Mechanisms by which SMARCB1 loss drives rhabdoid tumor growth. Kim KH; Roberts CW Cancer Genet; 2014 Sep; 207(9):365-72. PubMed ID: 24853101 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]